Study · Randomized controlled trial · n = 9,340 · 2017

4 results

Liraglutide and Renal Outcomes in Type 2 Diabetes.

Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB

The New England journal of medicine1 Aug 2017Cited by 920 (Europe PMC)

PMID28854085DOI10.1056/nejmoa1616011PepBankPUB-28854085

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and high cardiovascular risk, the composite renal outcome occurred in fewer patients with liraglutide than with placebo (hazard ratio 0.78).
In plain wordsIn adults with type 2 diabetes and high heart risk, fewer people on liraglutide had serious kidney outcomes than people on placebo.
Peptide
Liraglutide
Outcome
DecreaseComposite renal outcome
Study
n = 9,340
Comparator
Placebo
Analysis
Secondary
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
The renal outcome occurred in fewer participants in the liraglutide group than in the placebo group (268 of 4668 patients vs. 337 of 4672; hazard ratio, 0.78; 95% confidence interval [CI], 0.67 to 0.92; P=0.003).
3 context sentences(design, population, supporting numbers)
Summary · context
The secondary renal outcome was a composite of new-onset persistent macroalbuminuria, persistent doubling of the serum creatinine level, end-stage renal disease, or death due to renal disease.
Summary · context
We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo.
Summary · context
A total of 9340 patients underwent randomization, and the median follow-up of the patients was 3.84 years.
Report a problemFND-2885408501
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and high cardiovascular risk, new-onset persistent macroalbuminuria occurred in fewer patients with liraglutide than with placebo (hazard ratio 0.74).
In plain wordsIn adults with type 2 diabetes and high heart risk, fewer people on liraglutide developed lasting high protein in the urine than people on placebo.
Peptide
Liraglutide
Outcome
DecreaseNew-onset persistent macroalbuminuria
Study
n = 9,340
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
This result was driven primarily by the new onset of persistent macroalbuminuria, which occurred in fewer participants in the liraglutide group than in the placebo group (161 vs. 215 patients; hazard ratio, 0.74; 95% CI, 0.60 to 0.91; P=0.004).
2 context sentences(design, population, supporting numbers)
Summary · context
We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo.
Summary · context
A total of 9340 patients underwent randomization, and the median follow-up of the patients was 3.84 years.
Report a problemFND-2885408502
03HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes and high cardiovascular risk, rates of renal adverse events were similar with liraglutide and placebo (15.1 and 16.5 events per 1000 patient-years).
In plain wordsIn adults with type 2 diabetes and high heart risk, kidney side effects were about as common with liraglutide as with placebo.
Peptide
Liraglutide
Outcome
No significant changeRenal adverse events
Study
n = 9,340
Comparator
Placebo
Outcome group
Adverse events · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
The rates of renal adverse events were similar in the liraglutide group and the placebo group (15.1 events and 16.5 events per 1000 patient-years), including the rate of acute kidney injury (7.1 and 6.2 events per 1000 patient-years, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo.
Summary · context
A total of 9340 patients underwent randomization, and the median follow-up of the patients was 3.84 years.
Report a problemFND-2885408503
04HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes and high cardiovascular risk, acute kidney injury rates were similar with liraglutide and placebo (7.1 and 6.2 events per 1000 patient-years).
In plain wordsIn adults with type 2 diabetes and high heart risk, sudden kidney injury was about as common with liraglutide as with placebo.
Peptide
Liraglutide
Outcome
No significant changeAcute kidney injury
Study
n = 9,340
Comparator
Placebo
Outcome group
Adverse events · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
The rates of renal adverse events were similar in the liraglutide group and the placebo group (15.1 events and 16.5 events per 1000 patient-years), including the rate of acute kidney injury (7.1 and 6.2 events per 1000 patient-years, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo.
Summary · context
A total of 9340 patients underwent randomization, and the median follow-up of the patients was 3.84 years.
Report a problemFND-2885408504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials3

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

3 trials · 1 ongoing · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 3NCT06894784

A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes

McGill University Health Centre/Research Institute of the McGill University Health Centren = 36est. Apr 2025 to est. Jan 2027

Diabetes Type 1

Trial page ClinicalTrials.govUpdated 30 Mar 2025

Status unknownPhase 2NCT04529278

Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients

Fondation Hôpital Saint-Josephn = 1818 Jan 2021 to est. 31 Dec 2023

Diabetes Mellitus, Type 2 · Hemodialysis · Obese

Trial page ClinicalTrials.govUpdated 14 Apr 2023

CompletedPhase 3Results postedNCT01179048

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

Novo Nordisk A/Sn = 9,34131 Aug 2010 to 17 Dec 2015

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 17 Jul 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.